Strides Shasun today has received final USFDA approval for memantine hydrochloride tablets used in the treatment of dementia. The product will be manufactured at the company’s facility at Bengaluru and marketed by Strides Pharma Inc in the US market. It will be made available in strengths of 5mg and 10 mg. According to industry estimates, sales for memantine hydrochloride tablets USP, 5mg and 10 mg is approximately USD 60 million.
Company Profile : Shasun Pharmaceuticals Ltd
Leave a Reply